Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 9/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3380129 | 0.98 | LMNA (0.55) | LMNATSHRNPC1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL26618193 | 0.83 | TSHR (0.41) | LMNATSHRNPC1KMT2AKDM4E | |
| SCHEMBL10855093 | 0.77 | TSHR (0.48) | LMNATSHRNPC1MEN1KMT2A | |
| SCHEMBL12980713 | 0.76 | LMNA (0.61) | LMNATSHRNPC1MEN1KMT2A | |
| SCHEMBL1438711 | 0.76 | LMNA (0.55) | LMNATSHRNPC1MEN1KMT2A | |
| SCHEMBL1438716 | 0.76 | LMNA (0.55) | LMNATSHRNPC1MEN1KMT2A | |
| SCHEMBL8784070 | 0.76 | GAA (0.48) | LMNANPC1MEN1KMT2AKDM4E | |
| SCHEMBL11080638 | 0.76 | POLB (0.47) | TSHRNPC1KMT2AHPGDALDH1A1 | |
| SCHEMBL8077219 | 0.76 | CTSD (0.53) | LMNATSHRNPC1SMN1; SMN2GAA | |
| Hydrochloric Acid SCHEMBL1823566 | 0.74 | CTSD (0.52) | LMNATSHRNPC1SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113646317-A | Metal complexes | 默克专利有限公司 | 2021-11-12 | — | — | CN | disclosed |
| EP-2473486-B1 | PYRIMIDINES AS HEPCIDINE ANTAGONISTS | VIFOR INT AG (CH) | 2015-10-28 | — | — | EP | disclosed |
| US-20120202806-A1 | Novel Pyrimidine- And Triazine-Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-20120202806-A1 | Novel Pyrimidine- And Triazine-Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-09 | — | — | US | disclosed |
| CN-102482232-A | Novel pyrimidine and triazine hepcidin antagonists | VIFOR INT AG | 2012-05-30 | — | — | CN | disclosed |
| EP-1615897-B1 | PYRIMIDINONE COMPOUNDS AS CALCILYTICS | NPS PHARMA INC (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7491728-B2 | Pyrimidinone compounds as calcilytics | SMITHKLINE BEECHAM CORP. (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1615897-A4 | PYRIMIDINONE COMPOUNDS AS CALCILYTICS | NPS PHARMA INC (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20070197555-A1 | Pyrimidinone Compounds As Calcilytics | GLAXOSMITHKLINE LLC | 2007-08-23 | — | — | US | disclosed |
| EP-1615897-A2 | PYRIMIDINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004092120-A2 | PYRIMIDINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202806-A1 | Novel Pyrimidine- And Triazine-Hepcidine Antagonists | HAMP, DHPS, SLC40A1 | LMNA 4333/4885TSHR 851/4885NPC1 2222/4885 |
| US-20070197555-A1 | Pyrimidinone Compounds As Calcilytics | TYMP, DPYD, UMPS | LMNA 2078/4885TSHR 3381/4885NPC1 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.